Pfizer’s outlook disappoints after Viagra loses patent protection and Lyrica faces same fate

Health, Fitness & Food

Pharmaceutical giant Pfizer reported fourth-quarter earnings and revenue on Tuesday that beat Wall Street’s expectations but its guidance for 2019 disappointed investors.

shuffle the company’s senior management team in October, and has been focused on bulking up its pipeline of drugs and therapies, especially in oncology, ahead of impending patent expirations.

Shares of Pfizer have fallen more than 9 percent since the beginning of this year. The stock has increased more than 1 percent over the past 12 months.

Advertisements

Products You May Like

Articles You May Like

Computer use later in life may prevent cognitive decline
What are the signs of emotional abuse?
‘Simply seeing green spaces’ may help reduce cravings
What to know about eye floaters
Facts about skin cancer in black people

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.